Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
ABOUT TAKEDA PHARMACEUTICAL COMPANY LIMITED
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005289/en/
Website: https://www.takeda.com/
Contact
Takeda Pharmaceutical Company Limited
Media Contacts:
Japanese Media
Kazumi Kobayashi
+81 (0) 3-3278-2095
kazumi.kobayashi@takeda.com
Media Outside Japan
Holly Campbell
+1 617-588-9013
holly.campbell@takeda.com
Investor Relations:
Christopher O’Reilly
+81 (0) 3-3278-2543
christopher.oreilly@takeda.com
This news is a press release provided by Takeda Pharmaceutical Company Limited.
-
3월 4일 10:49
-
1월 31일 13:12